Tech
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long
Regeneron Pharmaceuticals and Sanofi have announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting
Key takeaways
- Regeneron and Sanofi expanded their antibody collaboration to include multiple next-generation, long-acting immunology antibodies.
- Regeneron will receive $1 billion upfront with potential for up to $7 billion in future milestone payments.
- The companies will equally share development and commercialization costs, as well as any future profits.
- The newly added assets include REGN20423, a long-acting IL-4xIL-13 bispecific, and two other long-acting preclinical antibodies.
- The companies have settled their prior collaboration-related litigation.
Regeneron Pharmaceuticals and Sanofi have announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting immunology antibodies to their alliance. Under the agreement, Regeneron will receive $1 billion upfront and is eligible for up to $7 billion in future milestone payments. The companies will equally share development and commercialization costs, as well as future profits. The expansion adds REGN20423 (a clinical-stage long-acting IL-13 monoclonal antibody), a long-acting IL-4xIL-13 bispecific, and two other long-acting preclinical antibodies from Regeneron to the alliance. Additionally, the companies have settled their prior collaboration-related litigation.
The expanded multi-billion dollar alliance accelerates the global development of next-generation immunology medicines.
In their words
“The Regeneron-Sanofi alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster.”
By the numbers
- $1B
- Upfront payment received by Regeneron
- $7B
- Potential future milestone payments to Regeneron
- 1.5M+
- People currently receiving Dupixent across nine indications
- 60+
- Countries where Dupixent has received regulatory approvals
- 20-year
- Duration of the collaboration between Regeneron and Sanofi
How it unfolded
- Companies announce expanded alliance and settle prior litigation
Turn stories like this into views
Ravenclip finds the Tech news, makes the video, and posts it before attention moves on.
Common questions
- What happened with Regeneron and Sanofi?
- Regeneron and Sanofi expanded their antibody collaboration to include multiple next-generation, long-acting immunology antibodies.
- Where can I read the original report?
- Read the full report at Globenewswire.
